Literature DB >> 25084548

Antileishmanial metabolites from Geosmithia langdonii.

Lourin G Malak1, Mohamed Ali Ibrahim, Daoud W Bishay, Afaf M Abdel-baky, Ahmed M Moharram, Babu Tekwani, Stephen J Cutler, Samir A Ross.   

Abstract

Antileishmanial bioassay guided fractionation of Geosmithia langdonii has resulted in the isolation and identification of two new compounds (1 and 2) together with 10 known compounds (3-12). The structures of the isolated metabolites were elucidated based on comprehensive 1D and 2D NMR spectroscopic data as well as mass spectrometry. The absolute configuration at C4, C5, and C6 of 2 was determined as R using a modified Mosher esterification method and NOESY correlations. The extracts and the isolated metabolites were evaluated for their antileishmanial activities. Compounds 3, 9, 11, and 12 were found to be active against Leishmania donovani with IC50 values of 6.9, 3.3, 8.5, and 9.2 μM, respectively, while compounds 1, 5, and 10 showed lower activities against L. donovani with IC50 values of 13.0, 47.3, and 34.0 μM, respectively.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25084548      PMCID: PMC4176393          DOI: 10.1021/np5000473

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


Leishmaniasis is a serious disease that affects human health, especially in developing countries.[1] According to a recent estimation by the World Health Organization (WHO), there are about 1.5–2 million new cases and 20,000 to 30,000 deaths annually. Leishmaniasis has been classified into three main clinical groups: The endemic visceral leishmaniasis (VL), also known as “Kala-azar”, is considered a life-threatening disease, as it interacts with HIV infection[2] and is accompanied by enlargement of the spleen and liver, weight loss, and anemia;[1,3] cutaneous leishmaniasis (CL) occurs in about 88 countries[5] (66 countries in Africa, Europe, and Asia and 22 countries in North/South America and Oceania) and can cause ulcers and severe disability;[1,3] and mucocutaneous leishmaniasis (ML) can lead to destruction of mucous membranes in the nose, mouth, and throat.[3,6] The currently used chemotherapeutic agents, both the first line of treatment such as the pentavalent antimonial compounds and the second line compounds including amphotericin B, have toxic side effects[7] and become less effective due to the emergence of resistant strains.[8,9] Thus, there is an urgent need for a new, effective, and inexpensive antileishmanial drug. Geosmithia langdonii (Ascomycota: Hypocreales) is a filamentous fungus and was provided by Assiut University Mycological Center (Accession No. 6161). In this study, G. langdonii fungus was grown using three different media [tryptic soy broth, malt extract broth, and potato dextrose broth (PDB)]. Ethyl acetate extracts were evaluated for antileishmanial activity, and the extract obtained from cultures grown in PDB showed the highest activity against Leishmania donovani with an IC50 value of 0.35 μg/mL, while extracts obtained by using tryptic soy and malt extract broth media exhibited IC50 values of 5.75 and 36.03 μg/mL, respectively (Table 1). The fungus was then cultivated on a large scale using PDB medium, which led to the production of seven active antileishmanial metabolites. Among the produced metabolites, compounds 4-[2′,4′-dihydroxy-6′-(hydroxymethyl)benzyl]benzene-1,2-diol (1) and (4R,5R,6R)-4,5-dihydroxy-6-(6′-methylsalicyloxy)-2-methyl-2-cyclohexen-1-one (2) were found to be new. Ten known compounds had been identified: (+)-epiepoformin (3), (−)-dihydroepiepoformin (4), (4S,5S)-4,5-dihydroxy-2-methylcyclohex-2-enone (5), 6-methylsalicylic acid (6), gentisylquinone (7), 3,4-dihydroxytoluene (8), 2,5-dihydroxybenzaldehyde (9), 3-hydroxybenzyl alcohol (10), 2,5-dihydroxybenzyl alcohol (11), and 3-hydroxytoluene (12) (Figure 1).
Table 1

Antileishmanial Activities of Ethyl Acetate Extracts of Geosmithia langdonii Obtained by Using Different Growth Media As Well As for the Isolated Metabolites, IC50 and IC90 (μM)

extract/compoundLeishmania donovani IC50 (μM)aLeishmania donovani IC90 (μM)b
GL-PDBc0.35f1.16f
GL-TSBd5.75f6.93f
GL-MEBe36.03f>40f
113.022.0
36.910.8
547.361.0
93.36.1
1034.052.3
118.510.4
129.212.4
pentamidine3.25.9
amphotericin B0.20.4

IC50 is the concentration that affords 50% inhibition of cell growth.

IC90 is the concentration that affords 90% inhibition of cell growth.

Ethyl acetate extract obtained by using potato dextrose broth medium.

Ethyl acetate extract obtained by using tryptic soy broth medium.

Ethyl acetate extract obtained by using malt extract broth medium. Test concentrations are 40, 8, and 1.6 μg/mL.

Expressed in μg/mL.

Figure 1

Structures of the isolated metabolites (1–12).

Structures of the isolated metabolites (1–12). IC50 is the concentration that affords 50% inhibition of cell growth. IC90 is the concentration that affords 90% inhibition of cell growth. Ethyl acetate extract obtained by using potato dextrose broth medium. Ethyl acetate extract obtained by using tryptic soy broth medium. Ethyl acetate extract obtained by using malt extract broth medium. Test concentrations are 40, 8, and 1.6 μg/mL. Expressed in μg/mL.

Results and Discussion

Compound 1 was obtained as white needles (CH3OH) and had a molecular formula of C14H14O5, which was determined on the basis of HRESIMS, showing eight degrees of unsaturation, suggesting the presence of two aromatic rings. The 13C NMR data (Table 2) showed five aromatic methines [δ 114.5 (C-5), 116.1 (C-5′), 116.8 (C-6), and 117.8 (C-3 and C-3′)], in addition to three quaternary and four oxygenated tertiary carbons [δ 126.9 (C-1′), 128.4 (C-6′), 129.5 (C-4), 148.1 (C-1), 148.3 (C-2′), 148.8 (C-4′), and 150.9 (C-2)]. Four of them are deshielded, suggesting their attachment to electron-withdrawing groups. The 1H NMR spectrum (Table 2) showed resonance for a diphenylmethylene group (δ 3.73, s) as well as an oxygenated methylene group (δ 4.53, s). The presence of two aromatic rings connected by a methylene group was further confirmed by the 3J HMBC correlations of H-8′ (δ 3.73, s) with C-3 (δ 117.8), C-6′ (δ 128.4), and C-2′ (δ 148.3). The full assignments of the protons and carbons were supported by the 2J and 3J HMBC correlations (SI). H-7′ (δ 4.53, s) showed 3J HMBC correlations with C-5′ (δ 116.1) and C-1′ (δ 126.9); H-5′ (δ 6.72, br s) showed 3J HMBC correlation with C-7′ (δ 60.8) and 2J HMBC correlations with C-4′ (δ 148.8) and C-6′ (δ 128.4); H-3′ (δ 6.51, br s) showed 3J HMBC correlations with C-5′ (δ 116.1) and C-1′ (δ 126.9); H-3 (δ 6.50, br s) showed 3J HMBC correlations with C-8′ (δ 30.7), C-5 (δ 114.5), and C-1 (δ 148.1); H-5 (δ 6.45, dd) showed 3J HMBC correlations with C-3 (δ 117.8) and C-1 (δ 148.1); H-6 (δ 6.59, d) showed 3J HMBC correlations with C-4 (δ 129.5) and C-2 (δ 150.9). Consequently, compound 1 was identified as 4-[2′,4′-dihydroxy-6′-(hydroxymethyl)benzyl]benzene-1,2-diol.
Table 2

1H and 13C NMR Spectroscopic Data of 1 and 2a

 1
2
positionδC, typeδH (J in Hz)δC, typeδH (J in Hz)
1148.1, C 194.4, C 
2150.9, C 134.1, C 
3117.8, CH6.50, br s150.0, CH7.04, br s
4129.5, C 72.8, CH5.00, d (8)
5114.5, CH6.45, dd (3.2, 8.4)77.5, CH4.59, dd (8, 11.2)
6116.8, CH6.59, d (8.4)80.1, CH6.23, d (11.6)
7  15.7, CH31.84, s
1′126.9, C 116.1, C 
2′148.3, C 160.0, C 
3′117.8, CH6.51, br s115.6, CH7.03, d (8)
4′148.8, C 133.5, CH7.27, t (8.4, 7.2)
5′116.1, CH6.72, br s122.9, CH6.76, d (7.6)
6′128.4, C 140.6, C 
7′60.8, CH24.53, s169.9, C 
8′30.7, CH23.73, s22.4, CH32.68, s

Data for 1 and 2 are in CD3OD and pyridine, respectively (400 MHz for 1H, 100 MHz for 13C, δ in ppm).

Data for 1 and 2 are in CD3OD and pyridine, respectively (400 MHz for 1H, 100 MHz for 13C, δ in ppm). Compound 2, with the molecular formula C15H16O6, revealed by HRESIMS, was obtained as colorless needles (CH3OH). The 1H and 13C NMR data (Table 2) showed three oxymethines at δ 6.23 (d, J = 11.6 Hz)/δ 80.1, δ 5.00 (d, J = 8 Hz)/δ 72.8 and δ 4.59 (dd, J = 8, 11.2 Hz)/δ 77.5 and one sp2 methine at δ 7.04 (br s)/δ 150.0; this was in addition to a carbonyl group at δ 194.4 and one methyl group at δ 1.84 (s)/δ 15.7. These signals were similar to those of 3 except for the downfield shifts of H-4/C-4 (from δ 4.52/62.8 in 3 to δ 5.00/72.8 in 2), H-5/C-5 (from δ 3.68/57.7 in 3 to δ 4.59/77.5 in 2), and H-6/C-6 (from δ 3.36/53.2 in 3 to δ 6.23/80.1 in 2). This in turn suggested the opening of the epoxide ring in 3, thus forming two hydroxy units in 2. In addition, the 1H and 13C NMR spectra of 2 showed signals similar to those of 6-methylsalicylic acid (6), suggesting the presence of a similar moiety in the form of an ester. This was confirmed by the 3J HMBC correlation of H-6 (δ 6.23, d) with the ester carbonyl carbon (δ 169.9) of the 6-methylsalicylic acid unit (SI), in addition to the downfield shifts of H-6/C-6 (δ 6.23/80.1). The structure was further confirmed by the 2J and 3J HMBC correlations (SI). H-3 (δ 7.04, br s) showed 3J HMBC correlations with C-5 (δ 77.5) and C-7 (δ 15.7); H-4 (δ 5.00, d) showed 3J HMBC correlation with C-2 (δ 134.1) and 2J HMBC correlations with C-5 (δ 77.5) and C-3 (δ 150.0); H-5 (δ 4.59, dd) showed 2J HMBC correlations with C-4 (δ 72.8) and C-6 (δ 80.1); H-6 (δ 6.23, d) showed 3J HMBC correlation with C-4 (72.8) and 2J HMBC correlations with C-1 (194.4) and C-5 (77.5); H-7 (δ 1.84, s) showed 3J HMBC correlations with C-1 (δ 194.4) and C-3 (δ 150.0) and 2J HMBC correlation with C-2 (δ 134.1); H-3′ (δ 7.03, d) showed 3J HMBC correlations with C-1′ (δ 116.1) and C-5′ (δ 122.9) and 2J HMBC correlation with C-2′ (δ 160.0); H-4′ (δ 7.27, t) showed 3J correlations with C-2′ (δ 160.0) and C-6′ (δ 140.6); H-5′ (δ 6.76, d) showed 3J HMBC correlations with C-8′ (δ 22.4), C-3′ (δ 115.6), and C-1′ (δ 116.1); and H-8′ (δ 2.68, s) showed 3J HMBC correlations with C-1′ (δ 116.1) and C-5′ (δ 122.9) and 2J HMBC correlation of C-6′ (δ 140.6). By comparing these spectral data with closely related published compounds,[8,9] compound 2 was identified as 4,5-dihydroxy-6-(6′-methylsalicyloxy)-2-methyl-2-cyclohexen-1-one. The absolute configuration of compound 2 was determined as R, using the modified Mosher esterification method,[10] by preparing the diastereoisomeric esters separately with (R)- and (S)-α-methoxy-α-trifluoromethylphenylacetyl chloride (MTPA-Cl), followed by analyzing their 1H NMR chemical shift differences [Δδ]. Utilizing the acid chloride of Mosher’s reagent rather than the free acid commonly used in the typical Mosher’s method enabled running the reactions in the NMR tubes and rapidly acquiring the data.[11] The 1H NMR Δδ of MTPA esters of the compound (pyridine-d5, 400 MHz) were assigned for the following protons: H-3 (−34 Hz), H-5 (−2.4 Hz), and H-6 (24.4 Hz). Analysis of the above Δδ values established that the C-5-OH group has an R-configuration. The absolute configurations of C-4-OH and C-6-OCO have been established to be R based on the NOESY correlations between H-3, H-4, and H-5. Compound 3 displayed a deprotonated molecular ion [M – H]− at m/z 139.040 99 (calcd 139.03951) in the negative mode HRESIMS, corresponding to a molecular formula of C7H8O3. The 1H and 13C NMR spectra showed the presence of three oxymethines; two are upfield shifted at δ 3.36 (d, J = 3.6 Hz)/δ 53.2 and δ 3.68 (dd, J = 0.8, 3.6 Hz)/δ 57.7, characterized for the epoxide, while the third oxymethine is at δ 4.52 (dd, J = 0.8, 4.8 Hz)/δ 62.8. Also, the spectra revealed the presence of one carbonyl carbon at δ 195.1, suggesting the presence of a cyclohexenone, which was confirmed by the presence of an sp2 methine at δ 6.37 (d, J = 1.2 Hz)/δC 139.8, a singlet corresponding to a methyl group at δ 1.70 (3H, s)/δC 15.7, and one quaternary carbon at δ 133.7. The interpretation of the HMQC and HMBC correlations led us to the complete assignment of the structure. The absolute configuration of C-4 of compound 3 was determined as S, using the Mosher esterification method. The 1H NMR Δδ of the MTPA esters of the compound (pyridine-d5, 400 MHz) were assigned for the following protons: H-5 (0 Hz) and H-4 (+48 Hz). Analysis of the above Δδ values established that the C-4 has an S-configuration. By comparing these data with those of closely related published compounds,[12] we concluded that compound 3 is (2R,3R,4S)-2,3-epoxy-4-hydroxy-6-methylcyclohex-5-enone [(+)-epiepoformin].[12] Nine known compounds had been identified: (−)-dihydroepiepoformin (4),[12] (4S,5S)-4,5-dihydroxy-2-methylcyclohex-2-enone (5), 6-methylsalicylic acid (6), gentisylquinone (7),[14] 3,4-dihydroxytoluene (8), 2,5-dihydroxybenzaldehyde (9), 3-hydroxybenzyl alcohol (10),[15] 2,5-dihydroxybenzyl alcohol (11),[16] and 3-hydroxytoluene (12). (+)-Epiepoformin, 2,5-dihydroxybenzaldehyde, 2,5-dihydroxybenzyl alcohol, and 3-hydroxytoluene were all found to have activities against L. donovani, with IC50 values of 6.9, 3.3, 8.5, and 9.2 μM, respectively, while compounds 1, (4S,5S)-4,5-dihydroxy-2-methylcyclohex-2-enone, and 10, 3-hydroxybenzyl alcohol have moderate activities against L. donovani, with IC50 values of 13.0, 47.3, and 34.0 μM, respectively (Table 1). All of the compounds were tested for antimicrobial activity, and only 3,4-dihydroxytoluene showed moderate antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Staph. aureus, with IC50 values of 72.9 and 147.8 μM, respectively, [ciprofloxacin showed IC50 of 0.1 μg/mL against MRSA and Staph. aureus; IC50 = the concentration that affords 50% inhibition of growth (μg/mL)].

Experimental Section

General Experimental Procedures

High-resolution mass spectra were measured using a Bruker BioApex spectrometer. 1D and 2D NMR spectra were recorded on a Varian AS 400 MHz spectrometer. Incubator shakers (New Brunswick Scientific, Innova 4430) were used for incubating fungi. Sephadex LH-20 (Mitsubishi Kagaku, Tokyo, Japan) and silica gel (60–120 mesh, Merck) were used for column chromatography (CC). Solid-phase extraction (SPE) cartridges (Supelco, silica, 2, 5, and 10 g) were used under vacuum. Fractions from CC were monitored using precoated aluminum sheets [silica 60 F254, 0.25 mm (Merck, Darmstadt, Germany)], with detection provided by UV light (254 and 366 nm) and by spraying with 1% vanillinsulfuric acid reagent followed by heating for 5–10 min (105 °C). Diaion HP-20 (250 μm, Sigma-Aldrich) was used for the separation of metabolites from the liquid media.

Fungal Material

Geosmithia langdonii (Ascomycota: Hypocreales) was provided by Assiut University Mycological Center, Assiut, Egypt. The fungus has been identified by one of the coauthors, Dr. A. M. Moharram, at Assiut University Mycological Center based on its morphological characters and comparison with the literature (Accession No. 6161).[17] This fungus was isolated from 100% cotton textiles, Assiut, Egypt. The textiles were rinsed with water followed by surface sterilization in 70% EtOH for 1 min, rinsed with sterilized water, cut into small pieces (2 cm in length and width), deposited on a Petri dish containing modified PDA medium (200 g of potato, 20 g of glucose, and 15 g of agar in 1 L of distilled water, supplemented with 100 mg/L chloramphenicol), and cultivated at 28 °C for 3 days. The hypha tips were observed and transferred to new PDA plates and subcultured until pure culture was obtained.

Culture Media

Fungi were grown on modified potato dextrose agar (PDA) plates at 28 °C for 14 days. Plates were kept in a refrigerator and used when needed. The fungus was grown on tryptic soy, malt extract, and PDB media.

Extraction and Isolation of Bioactive Metabolites

For small-scale extractions, the fungi were grown on a small scale using tryptic soy broth, malt extract broth, and PDB media. Fifty milliliters of each media were placed in 125 mL conical flasks and incubated with small pieces of actively growing mycelium. The cultures were incubated at 30 °C under orbital agitation (160 rpm) for 14 days. After incubation, the contents of the flasks were filtered through sterile cotton using vacuum filtration, and then the filtrates were extracted exhaustively with ethyl acetate. The organic phase was vacuum concentrated to afford the extracts, which were then submitted for biological assays. G. langdonii was grown in 2800 mL Erlenmeyer flasks containing 1 L of PDB medium (36 flasks), which had been prepared by dissolving 24 g of PDB in 1 L of distilled water and then autoclaved. Each flask was seeded by small fragments (∼2–5 mm) of the mycelium. The fungi were incubated at 30 °C, using shakers (160 rpm), for 2 weeks. After the incubation period, the mycelia were filtered through sterile cotton using vacuum filtration, and the filtrates (40 L) were extracted with activated ion-exchange resin (Diaion HP-20) by adding 100 g of resin to each 1 L of filtrate before being returned to the shakers and left overnight. The contents of the flasks were then filtered, and the HP-20 was washed with distilled water to remove salts and sugars. Then, the resin was eluted with MeOH and acetone. The MeOH and acetone eluates were combined and dried under vacuum to yield a viscous residue, which was dissolved in water and successively extracted with n-hexane, DCM, and EtOAc (each 4 × 1 L). Each solvent was separately concentrated under vacuum to afford 2 g (n-hexane), 10 g (DCM), and 2 g (EtOAc). The crude DCM extract (10 g) was subjected to vacuum liquid chromatography (VLC) on flash silica gel (200 g, 15 × 15 cm) and eluted with gradients of n-hexaneEtOAc (80:20–100:0) and then with EtOAcMeOH gradients (90:10–50:50) to afford nine fractions [A–I]. Fraction B (eluted with n-hexaneEtOAc, 4:1, 385 mg) was chromatographed over silica gel CC (9 g, 50 × 3.5 cm) and eluted with n-hexaneEtOAc gradients (100:0–80:20, 100 mL/fraction) to give five subfractions (B1–B5). Subfraction B3 (eluted with n-hexaneEtOAc, 93:7, 195 mg) was further purified on Sephadex LH-20 CC (10 g, 65 × 1.5 cm) with MeOHCHCl3 (1:1) as eluent, yielding 9 (85 mg). Fraction C (eluted with n-hexaneEtOAc, 3:1, 460 mg) was subjected to solid-phase separation using an SPE cartridge (silica, 10 g) under vacuum and eluted with n-hexaneEtOAc with increasing polarities (95:5–50:50, 150 mL/fraction) to afford six subfractions (C1–C6). Subfraction C3 (eluted with n-hexaneEtOAc, 17:3, 240 mg) was chromatographed over Sephadex LH-20 CC (15 g, 65 × 1.5 cm), using MeOHCHCl3 (50:50) as the eluent, to yield subfraction C3-1 (170 mg) and 8 (35 mg). Subfraction C3-1 (170 mg) was further purified by CC over silica gel (5 g, 25 × 1.5 cm) using n-hexaneEtOAc (95:5–85:15, 50 mL/fraction) to yield 3 (30 mg), 4 (1.5 mg), and 2 (5 mg). Fraction H (eluted with EtOAcMeOH, 3:1, 2 g) was subjected to silica gel CC (50 g, 65 × 5 cm) using stepwise gradient elution of EtOAc and MeOH (90:10–70:30, 2 L/fraction) to yield three subfractions [H1–H3]. Subfraction H1 (eluted with EtOAcMeOH, 9:1, 200 mg) was further purified by Sephadex LH-20 CC (15 g, 65 × 1.5 cm) and eluted with MeOHCHCl3 (1:1) to afford 6 (4 mg). The EtOAc crude extract (2 g) was subjected to silica gel CC (50 g, 65 × 5 cm) and eluted with n-hexaneEtOAc in a manner of increasing polarities (100:0–0:100, 2 L/fraction) to afford 10 fractions [A–J]. Fraction B yielded 10 (45 mg). Fractions C, D, E, and F were further purified by Sephadex LH-20 CC (15 g, 65 × 1.5 cm) and eluted with MeOHCHCl3 (50:50), yielding 7 (3 mg), 11 (53 mg), 5 (2.5 mg), and 1 (3.5 mg), respectively. The crude n-hexane extract (2 g) was subjected to silica gel CC (50 g, 65 × 5 cm) and eluted with n-hexaneEtOAc with increasing polarities (100:0–70:30, 1 L each) to afford five fractions [A–E]. Fraction C yielded 12 (2 mg).

4-[2′,4′-Dihydroxy-6′-(hydroxymethyl]benzyl)benzene-1,2-diol (1):

white needles (CH3OH); UV (MeOH) λmax (log ε) 298 (3.01) and 315 (3.24) nm; 1H NMR (CD3OD, 400 MHz) see Table 2; 13C NMR (CD3OD, 400 MHz) see Table 2; HRESIMS m/z 261.06980 [M – H]− (calcd for C14H14O5, 261.07629).

(4R,5R,6R)-4,5-Dihydroxy-6-(6′-methylsalicyloxy)-2-methyl-2-cyclohexen-1-one (2):

colorless needles (CH3OH); [α]25D −124 (c 0.06, MeOH); UV (MeOH) λmax(log ε) 296 (3.47), 308 (3.51), and 318 (3.45) nm; 1H NMR (pyridine-d5, 400 MHz) see Table 2; 13C NMR (pyridine-d5, 400 MHz) see Table 2; HRESIMS m/z 315.0823 [M + Na]+ and 607.1724 [2M + Na]+ (calcd for C15H16O6Na 315.08448 and C30H32O12Na 607.17916, respectively).

Determination of the Absolute Configuration

In order to determine the absolute configuration, a modified Mosher esterification method was used, where the diastereomeric (R)- and (S)-α-methoxy-α-trifluoromethylphenylacetyl chloride (MTPA-Cl) esters of the compound were prepared in NMR tubes. First, the compound was mixed with (R)- and (S)-MTPA-Cl separately in two different NMR tubes, in pyridine-d5 with a molar ratio of 1:1, respectively. The mixtures in the NMR tubes were warmed to 60–70 °C for 2–3 min, followed by acquiring the 1H NMR spectra for both the diastereoisomeric MTPA esters, and then their chemical shift differences [i.e., Δδ = δ(S-MTPA ester – δ(R-MTPA ester)] were analyzed and calculated.[10]

Antileishmanial Bioassay

The antileishmanial activity was evaluated against a culture of L. donovani promastigotes grown in RPMI 1640 medium supplemented with 10% GIBCO fetal calf serum at 26 °C. Growth of leishmanial promastigotes was determined by the Alamar Blue assay (BioSource International, Camarillo, CA, USA). Standard fluorescence was measured by a Fluostar Galaxy plate reader (excitation wavelength, 544 nm; emission wavelength, 590 nm).[18,19] Pentamidine (IC50 3.2 μM and IC90 5.9 μM) and amphotericin B (IC50 0.2 μM and IC90 0.4 μM) were used as the controls.

Antimicrobial Bioassay

Pure compounds were tested for antimicrobial activity against the fungi Candida albicans ATCC 90028, C. glabrata ATCC 90030, C. krusei ATCC 6258, and Aspergillus fumigates ATCC 90906, as well as the bacteria methicillin-resistant Staphylococcus aureus ATCC 33591, Cryptococcus neoformans ATTC 90113, Staphylococcus aureus ATTC 29213, Escherichia coli ATCC 35218 , Pseudomonas aeruginosa ATCC 27853, and Mycobacterium intracellulare ATCC 23068.[20] Amphotericin B (ICN Biomedicals, Aurora, Ohio) for fungal and ciprofloxacin (ICN Biomedicals) for bacterial bioassays were used as positive controls, respectively.
  15 in total

1.  A complex of three new white-spored, sympatric, and host range limited Geosmithia species.

Authors:  Miroslav Kolarík; Alena Kubátova; Ivan Cepicka; Sylvie Pazoutovtá; Petr Srůtka
Journal:  Mycol Res       Date:  2005-12

2.  Enantioselective synthesis of natural polyoxygenated cyclohexanes and cyclohexenes from [(p-tolylsulfinyl)methyl]-p-quinols.

Authors:  M Carmen Carreño; Estíbaliz Merino; María Ribagorda; Alvaro Somoza; Antonio Urbano
Journal:  Chemistry       Date:  2007       Impact factor: 5.236

Review 3.  The increase in risk factors for leishmaniasis worldwide.

Authors:  P Desjeux
Journal:  Trans R Soc Trop Med Hyg       Date:  2001 May-Jun       Impact factor: 2.184

4.  Antimicrobial and antileishmanial activities of hypocrellins A and B.

Authors:  Guoyi Ma; Shabana I Khan; Melissa R Jacob; Babu L Tekwani; Zuqiang Li; David S Pasco; Larry A Walker; Ikhlas A Khan
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS.

Authors:  C Montalban; J L Calleja; A Erice; F Laguna; B Clotet; D Podzamczer; J Cobo; J Mallolas; M Yebra; A Gallego
Journal:  J Infect       Date:  1990-11       Impact factor: 6.072

6.  Antiprotozoal and antimicrobial activities of O-alkylated and formylated acylphloroglucinols.

Authors:  Sandip B Bharate; Shabana I Khan; Nafees A M Yunus; Siddheshwar K Chauthe; Melissa R Jacob; Babu L Tekwani; Ikhlas A Khan; Inder Pal Singh
Journal:  Bioorg Med Chem       Date:  2006-10-10       Impact factor: 3.641

7.  Comparison of alamar blue and MTT assays for high through-put screening.

Authors:  R Hamid; Y Rotshteyn; L Rabadi; R Parikh; P Bullock
Journal:  Toxicol In Vitro       Date:  2004-10       Impact factor: 3.500

8.  Pentacyclic ingamine alkaloids, a new antiplasmodial pharmacophore from the marine sponge Petrosid Ng5 Sp5.

Authors:  Muhammad Ilias; Mohamed A Ibrahim; Shabana I Khan; Melissa R Jacob; Babu L Tekwani; Larry A Walker; Vladimir Samoylenko
Journal:  Planta Med       Date:  2012-08-17       Impact factor: 3.352

Review 9.  Leishmaniasis: current situation and new perspectives.

Authors:  P Desjeux
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2004-09       Impact factor: 2.268

10.  New chemical constituents of Euphorbia quinquecostata and absolute configuration assignment by a convenient Mosher ester procedure carried out in NMR tubes.

Authors:  Bao-Ning Su; Eun Jung Park; Zakaria H Mbwambo; Bernard D Santarsiero; Andrew D Mesecar; Harry H S Fong; John M Pezzuto; A Douglas Kinghorn
Journal:  J Nat Prod       Date:  2002-09       Impact factor: 4.050

View more
  5 in total

1.  Bioactive polyketides from the pathogenic fungus of Epicoccum sorghinum.

Authors:  Ching-Chia Chang; Chi-Ying Li; Yi-Hong Tsai; Mohamed El-Shazly; Chien-Kei Wei; Zih-Jie Yang; Shu-Li Chen; Chin-Chung Wu; Yang-Chang Wu; Fang-Rong Chang
Journal:  Planta       Date:  2021-05-06       Impact factor: 4.116

2.  Epigenetic Modifiers Induce Bioactive Phenolic Metabolites in the Marine-Derived Fungus Penicillium brevicompactum.

Authors:  Seham S El-Hawary; Ahmed M Sayed; Rabab Mohammed; Hossam M Hassan; Mohamed A Zaki; Mostafa E Rateb; Tarek A Mohammed; Elham Amin; Usama Ramadan Abdelmohsen
Journal:  Mar Drugs       Date:  2018-07-30       Impact factor: 5.118

3.  Anti-inflammatory, Antiplatelet Aggregation, and Antiangiogenesis Polyketides from Epicoccum sorghinum: Toward an Understating of Its Biological Activities and Potential Applications.

Authors:  Chi-Ying Li; Ching-Chia Chang; Yi-Hong Tsai; Mohamed El-Shazly; Chin-Chung Wu; Shih-Wei Wang; Tsong-Long Hwang; Chien-Kei Wei; Judit Hohmann; Zih-Jie Yang; Yuan-Bin Cheng; Yang-Chang Wu; Fang-Rong Chang
Journal:  ACS Omega       Date:  2020-05-06

4.  Metabolic and pharmacological profiling of Penicillium claviforme by a combination of experimental and bioinformatic approaches.

Authors:  Zafar Ali Shah; Khalid Khan; Zafar Iqbal; Tariq Masood; Hassan A Hemeg; Abdur Rauf
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

Review 5.  The Search for Putative Hits in Combating Leishmaniasis: The Contributions of Natural Products Over the Last Decade.

Authors:  Patrick O Sakyi; Richard K Amewu; Robert N O A Devine; Emahi Ismaila; Whelton A Miller; Samuel K Kwofie
Journal:  Nat Prod Bioprospect       Date:  2021-07-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.